Complete Freund's Adjuvant (CFA) induced Inflammatory Pain Model Development Service

Are you currently facing long drug development cycles and challenges in preclinical pain assessment? Our complete freund's adjuvant (CFA)-induced inflammatory pain model development service helps you accelerate analgesic drug discovery and obtain high-quality, translational data through advanced animal model development, comprehensive behavioral phenotyping, and in-depth mechanistic analysis.

Chronic inflammatory pain represents a major global health challenge, significantly impacting patient quality of life and imposing substantial economic burdens. Effective therapeutic development relies on robust preclinical models that accurately recapitulate human disease pathology. The CFA model is a widely accepted and validated in vivo platform that induces a persistent inflammatory state, making it invaluable for investigating pain mechanisms and screening novel analgesic compounds. Its utility extends to mimicking complex conditions like rheumatoid arthritis, providing critical translational insights.

How Our CFA-induced Inflammatory Pain Model Development Service Can Assist Your Project

Our service provides precise, reproducible preclinical data essential for advancing novel analgesic and anti-inflammatory compounds. We deliver a comprehensive understanding of your compound's efficacy and mechanism of action within a clinically relevant inflammatory pain model. Expect tailored solutions that address specific research questions, from screening early-stage candidates to detailed characterization of lead compounds. Our expertise ensures reliable outcomes that streamline your drug development pipeline.

Discover How We Can Help - Request a Consultation.

Workflow

Our workflow is designed for clarity, efficiency, and scientific rigor, ensuring a seamless experience from project initiation to final data delivery.

• Required Starting Materials:

To initiate your CFA-induced inflammatory pain model development project, we typically require:

1. Compound Information: Details on your test compound(s), including chemical structure (if applicable), solubility, stability, and desired dosing regimen.
2. Study Objectives: A clear outline of your research goals, such as primary efficacy endpoints, desired duration of pain, and specific mechanistic insights sought.
3. Desired Readouts: Any specific behavioral, biochemical, or histological endpoints beyond our standard offerings that are critical for your project.

• Final Deliverables:

Upon completion of your project, you will receive:

1. Comprehensive Study Report: A detailed document outlining the experimental design, methods, raw data, statistical analysis, and interpretation of results.
2. Raw Data Files: All raw behavioral, biochemical, and histological data in a readily accessible format.
3. Presentation of Key Findings: A summary presentation highlighting the most critical results and their implications for your drug discovery program.

• Estimated Timeframe:

The typical timeframe for this service ranges from 4 to 8 weeks, depending on the complexity of the study design, the number of compounds tested, and the depth of ex vivo analyses required. Chronic studies with longer observation periods will naturally extend the duration.

Why Choose Us?

Choosing CBL for your CFA-induced inflammatory pain model development service means partnering with a leader in preclinical pain research. Our expertise, advanced capabilities, and commitment to scientific excellence set us apart, ensuring your projects yield high-quality, actionable data.

We combine over two decades of experience with state-of-the-art facilities and a deep understanding of pain pathophysiology. Our rigorous protocols, including dose optimization studies (e.g., validating 10 mg/mL CFA for robust RA-like models), ensure high reproducibility and translational relevance. We offer a comprehensive suite of readouts, from precise behavioral phenotyping (mechanical allodynia, thermal hyperalgesia, spontaneous activities) to in-depth mechanistic analyses (metabolomics, histology, hematology), providing a holistic view of your compound's effects.

CFA-induced Inflammatory Pain Model

The CFA-induced inflammatory pain model is a cornerstone in preclinical pain research, renowned for its ability to create a reliable and reproducible inflammatory pain state in laboratory animals, primarily rodents. This model is particularly valuable for studying both peripheral and central mechanisms of inflammatory pain.

• Model Induction and Validation:

Our standard protocol involves a single intradermal injection of CFA, often optimized at 10 mg/mL into the hind metatarsal footpad for models mimicking polyarthritic rheumatoid arthritis. This leads to a consistent inflammatory response peaking around 24 hours and persisting for over 30 days, allowing for both acute and chronic pain studies.

• Key Readouts and Endpoints:

Comprehensive characterization of the CFA model involves a multi-modal assessment approach:

Behavioral Assessments:

Inflammatory Parameters:

This comprehensive approach ensures that the CFA-induced inflammatory pain model developed by CBL provides robust, reliable, and highly translational data for your analgesic drug discovery programs.

Customer Reviews

"Exceptional Data Quality. Using CBL's CFA-induced inflammatory pain model development service in our research has significantly improved the reliability and depth of our preclinical pain data, allowing us to make more confident decisions about our lead compounds." - July 2024, Dr. A***n

"Streamlined Workflow. The comprehensive workflow provided by CBL, from initial consultation to detailed reporting, has greatly facilitated our analgesic screening process, saving us valuable time and resources." - May 2024, S***h K.

"Unparalleled Expertise. The team at CBL demonstrated unparalleled scientific knowledge in optimizing the CFA model for our specific RA-mimicking study, providing insights into both behavioral and systemic inflammatory markers that were crucial for our project." - April 2025, Prof. M***a L.

What We Offer

At CBL, we are committed to providing a superior CFA-induced inflammatory pain model development service, fully customizable to your unique research needs. Our offerings are designed to empower biology experts like you with robust, reliable, and highly translational preclinical data.

• Customized Study Design: Tailored protocols for CFA induction, including dose optimization (e.g., 10 mg/mL for polyarthritic RA-like models), administration routes, and study duration to precisely match your specific research objectives and compound characteristics.
• Comprehensive Behavioral Phenotyping: In-depth assessment of nociceptive behaviors, including mechanical allodynia (Von Frey), thermal hyperalgesia (plantar test, hot plate), cold allodynia, and spontaneous activity scoring (standing and walking paw pressures) for a complete pain profile.
• Advanced Mechanistic Insights: Integration of cutting-edge analyses such as metabolomics profiling of spinal cord tissues to identify altered metabolic pathways and potential biomarkers, alongside traditional biochemical assays (e.g., cytokine analysis).
• Detailed Histopathological Evaluation: Microscopic examination of paw tissue and ankle joints to assess inflammatory cell infiltration, synovial hyperplasia, and structural changes like cartilage degradation and bone erosion, providing visual evidence of disease progression and therapeutic impact.
• Systemic Inflammatory Assessment: Comprehensive hematological analysis, including full blood counts, to monitor systemic inflammatory markers and other physiological changes relevant to chronic inflammatory conditions.
• Expert Consultation & Support: Direct access to our team of experienced biology specialists for scientific guidance, experimental design, data interpretation, and troubleshooting throughout your project.
• High-Quality, Actionable Data: Delivery of meticulously collected, statistically analyzed data presented in comprehensive reports, ready for your internal decision-making or regulatory submissions.

Related Services

To further support your drug discovery efforts, CBL offers a suite of complementary preclinical services that can be integrated with our CFA-induced inflammatory pain model development service:

• Chronic Inflammatory Disease Models
• Neuropathic Pain Models
• Custom Assay Development
• Pharmacokinetic/Pharmacodynamic (PK/PD) Studies

Ready to advance your pain research? Our team of expert scientists is eager to discuss your specific project requirements and demonstrate how our CFA-induced inflammatory pain model development service can provide the critical data you need.

Contact Our Team for More Information and to Discuss Your Project.